Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

ARTEMIP

Financiado

Cerrado

THE SAFETY PHARMACOLOGY OF ARTEMISININS WHEN USED TO REVERSE PATHOPHYSIOLOGY OF...

THE SAFETY PHARMACOLOGY OF ARTEMISININS WHEN USED TO REVERSE PATHOPHYSIOLOGY OF MALARIA IN PREGNANCY Artemisinin based antimalarial drug combinations are recommended for the treatment of P.falciparum malaria infections throughout all malarial endemic areas of the world and in all populations, including women of child bearing age.... ver más

31/08/2011

LIVERPOOL SCHOOL O...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

LIVERPOOL SCHOOL OF TROPICAL MEDICINE No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 6 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-08-31 No tenemos la información de la convocatoria

0% 75% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

6 Participantes

LIVERPOOL SCHOOL OF TROPICAL...

0.00€ | Lider

UALG

N.D. | Participante

THE UNIVERSITY OF LIVERPOOL

N.D. | Participante

UGOT - GOETEBORGS UNIVERSITE...

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAFIRE SAFETY OF ANTIMALARIALS IN THE FIRST TRIMESTER: AN ADAPTIVE... 5M€ Cerrado

PYRAPREG-extended Efficacy and Safety of a newly registered Artemisinin-Based... 2M€ Cerrado

GLOBALMED Artemisinin based combination therapy an illustration of th... 927K€ Cerrado

MARC SE-Africa Mitigating Antimalarial Resistance Consortium in South East... 4M€ Cerrado

ASAAP-plus Clinical evaluation of AntimalarialS tri-therapy with AtovAq... 1M€ Cerrado

IMPRIMA Implementing Primaquine Single Low Dose in Africa 4M€ Cerrado

Líder del proyecto

LIVERPOOL SCHOOL OF TROPICAL MEDICINE No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Artemisinin based antimalarial drug combinations are recommended for the treatment of P.falciparum malaria infections throughout all malarial endemic areas of the world and in all populations, including women of child bearing age. The studies planned in this collaborative project are central to assessing the potential hazard posed by these drugs to the developing human foetus and thereby making evidence based recommendations on the risk:benefit of these drugs. Although clinical experience to date indicates the artemisinins to be safe, the area of reproductive toxicology demands special consideration. Data from the Chinese literature and our own studies confirm that the artemisinins are embryotoxic and potentially teratogenic in animal species at drug doses within the human therapeutic range. Based on over ten years of investigating the pharmacology of these drugs we have developed a hypothesis which can explain these teratogenic effects. Our hypothesis is based on the generation of reactive oxygen species (ROS) from cleavage of the artemisinin peroxide bridge and consequent embryofoetal damage to key biological macromolecules. Our hypothesis draws on parallels with the metabolic activation and teratogenic effects of the other established teratogens such as phenytoin

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores